Takeda Pharmaceutical Co Stock Buy Hold or Sell Recommendation
| TAK Stock | USD 13.86 0.24 1.76% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Takeda Pharmaceutical Co is 'Cautious Hold'. The recommendation algorithm takes into account all of Takeda Pharmaceutical's available fundamental, technical, and predictive indicators you will find on this site.
Check out Takeda Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Takeda and provide practical buy, sell, or hold advice based on investors' constraints. Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Takeda |
Execute Takeda Pharmaceutical Buy or Sell Advice
The Takeda recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Takeda Pharmaceutical Co. Macroaxis does not own or have any residual interests in Takeda Pharmaceutical Co or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Takeda Pharmaceutical's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Takeda Pharmaceutical Trading Alerts and Improvement Suggestions
| Takeda Pharmaceutical generated a negative expected return over the last 90 days | |
| Takeda Pharmaceutical has a strong financial position based on the latest SEC filings | |
| Latest headline from medcitynews.com: Roche Expands Its Scope in Allogeneic Cell Therapy With 1B Poseida Therapeutics Acquisition |
Takeda Pharmaceutical Returns Distribution Density
The distribution of Takeda Pharmaceutical's historical returns is an attempt to chart the uncertainty of Takeda Pharmaceutical's future price movements. The chart of the probability distribution of Takeda Pharmaceutical daily returns describes the distribution of returns around its average expected value. We use Takeda Pharmaceutical Co price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Takeda Pharmaceutical returns is essential to provide solid investment advice for Takeda Pharmaceutical.
| Mean Return | -0.1 | Value At Risk | -1.91 | Potential Upside | 1.21 | Standard Deviation | 0.88 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Takeda Pharmaceutical historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Takeda Stock Institutional Investors
| Shares | Northern Trust Corp | 2024-09-30 | 1.6 M | Managed Asset Portfolios, Llc | 2024-09-30 | 1.6 M | Envestnet Asset Management Inc | 2024-09-30 | 1.4 M | Blackrock Inc | 2024-06-30 | 1.4 M | Causeway Capital Management Llc | 2024-09-30 | 1.3 M | Wells Fargo & Co | 2024-09-30 | 978 K | Bank Of America Corp | 2024-06-30 | 867.1 K | Jane Street Group Llc | 2024-06-30 | 603.8 K | Federated Hermes Inc | 2024-09-30 | 542.8 K | Capital Research Global Investors | 2024-09-30 | 13.1 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 5.4 M |
Takeda Pharmaceutical Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 137.5B | 26.0B | (46.1B) | (79.2B) | (115.7B) | (110.0B) | |
| Change In Cash | (65.1B) | 328.6B | (116.5B) | (316.2B) | (75.7B) | (71.9B) | |
| Free Cash Flow | 452.0B | 774.5B | 937.1B | 343.5B | 235.6B | 295.4B | |
| Depreciation | 583.6B | 559.7B | 583.2B | 664.4B | 728.0B | 764.4B | |
| Other Non Cash Items | 23.1B | (228.4B) | 95.4B | (97.7B) | 120.8B | 126.9B | |
| Dividends Paid | 282.6B | 283.4B | 283.7B | 279.4B | 287.2B | 158.3B | |
| Capital Expenditures | 217.7B | 236.5B | 186.0B | 633.7B | 480.7B | 504.8B | |
| Net Income | 44.3B | 376.2B | 230.2B | 317.0B | 144.1B | 217.6B | |
| End Period Cash Flow | 637.6B | 966.2B | 849.7B | 533.5B | 457.8B | 626.2B | |
| Investments | 292.1B | 62.0B | (198.1B) | (607.1B) | (463.9B) | (487.1B) | |
| Net Borrowings | (586.1B) | (660.5B) | (600.5B) | (285.1B) | (256.6B) | (243.7B) | |
| Change To Netincome | (75.3B) | (200.5B) | 169.9B | 21.0B | 24.2B | 25.4B |
Takeda Pharmaceutical Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Takeda Pharmaceutical or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Takeda Pharmaceutical's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Takeda stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.12 | |
β | Beta against Dow Jones | 0.01 | |
σ | Overall volatility | 0.89 | |
Ir | Information ratio | -0.28 |
Takeda Pharmaceutical Volatility Alert
Takeda Pharmaceutical Co exhibits very low volatility with skewness of -0.92 and kurtosis of 1.63. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Takeda Pharmaceutical's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Takeda Pharmaceutical's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Takeda Pharmaceutical Fundamentals Vs Peers
Comparing Takeda Pharmaceutical's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Takeda Pharmaceutical's direct or indirect competition across all of the common fundamentals between Takeda Pharmaceutical and the related equities. This way, we can detect undervalued stocks with similar characteristics as Takeda Pharmaceutical or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Takeda Pharmaceutical's fundamental indicators could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Takeda Pharmaceutical to competition |
| Fundamentals | Takeda Pharmaceutical | Peer Average |
| Return On Equity | 0.0415 | -0.31 |
| Return On Asset | 0.0278 | -0.14 |
| Profit Margin | 0.06 % | (1.27) % |
| Operating Margin | 0.21 % | (5.51) % |
| Current Valuation | 70.22 B | 16.62 B |
| Shares Outstanding | 3.17 B | 571.82 M |
| Shares Owned By Insiders | 0.01 % | 10.09 % |
| Shares Owned By Institutions | 2.40 % | 39.21 % |
| Number Of Shares Shorted | 5.66 M | 4.71 M |
| Price To Earning | 27.57 X | 28.72 X |
| Price To Book | 0.94 X | 9.51 X |
| Price To Sales | 0.01 X | 11.42 X |
| Revenue | 4.26 T | 9.43 B |
| Gross Profit | 2.44 T | 27.38 B |
| EBITDA | 900.33 B | 3.9 B |
| Net Income | 144.07 B | 570.98 M |
| Cash And Equivalents | 533.53 B | 2.7 B |
| Cash Per Share | 208.91 X | 5.01 X |
| Total Debt | 5.46 T | 5.32 B |
| Debt To Equity | 0.81 % | 48.70 % |
| Current Ratio | 1.18 X | 2.16 X |
| Book Value Per Share | 4,366 X | 1.93 K |
| Cash Flow From Operations | 716.34 B | 971.22 M |
| Short Ratio | 3.88 X | 4.00 X |
| Earnings Per Share | 0.60 X | 3.12 X |
| Price To Earnings To Growth | 0.70 X | 4.89 X |
| Target Price | 2471.44 | |
| Number Of Employees | 49.28 K | 18.84 K |
| Beta | 0.46 | -0.15 |
| Market Capitalization | 43.18 B | 19.03 B |
| Total Asset | 15.11 T | 29.47 B |
| Retained Earnings | 1.39 T | 9.33 B |
| Working Capital | 245.48 B | 1.48 B |
Takeda Pharmaceutical Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Takeda . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 51657.32 | |||
| Daily Balance Of Power | 0.8571 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 13.77 | |||
| Day Typical Price | 13.8 | |||
| Price Action Indicator | 0.21 | |||
| Period Momentum Indicator | 0.24 |
About Takeda Pharmaceutical Buy or Sell Advice
When is the right time to buy or sell Takeda Pharmaceutical Co? Buying financial instruments such as Takeda Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Takeda Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hedge Favorites Thematic Idea Now
Hedge Favorites
Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques. The Hedge Favorites theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hedge Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Takeda Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.6 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.